Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. COR
COR logo

COR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
362.270
Open
360.480
VWAP
355.30
Vol
970.83K
Mkt Cap
70.38B
Low
351.430
Amount
344.93M
EV/EBITDA(TTM)
15.28
Total Shares
194.53M
EV
76.74B
EV/OCF(TTM)
17.89
P/S(TTM)
0.22
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Show More

Events Timeline

(ET)
2026-02-04
06:40:00
Cencora Sees FY26 Adjusted Free Cash Flow Around $3B
select
2026-02-04
06:40:00
Raises FY26 Revenue Growth Outlook to 7%-9%
select
2026-02-04
06:40:00
Cencora Reports Q1 Revenue of $85.9B
select
2026-01-29 (ET)
2026-01-29
16:20:00
Microsoft Cloud Revenue Growth Misses Expectations, Nasdaq Closes Broadly Lower
select

News

Barron's
4.5
03-02Barron's
Three Key Sectors to Monitor While the S&P 500 Moves Sideways
  • Geopolitical Concerns: Ongoing geopolitical issues, including tensions related to Iran and international trade, are impacting market sentiment.

  • Tech Sector Pressures: The tech sector is facing challenges, particularly due to concerns surrounding artificial intelligence.

  • Investor Behavior: Instead of withdrawing from equities, investors are shifting their focus within the market.

  • Market Opportunities: This rotation in investment strategy is creating new pockets of opportunity for investors.

Fool
6.5
02-27Fool
TimesSquare Capital Increases ESAB Holdings by 262,850 Shares
  • Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed an increase of 262,850 shares in ESAB during Q4, representing an estimated trade value of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
  • Asset Allocation Shift: This acquisition raised ESAB's share to 1.61% of TimesSquare's 13F assets under management, reflecting the firm's strategic focus on this sector and enhancing ESAB's market position.
  • Market Performance Analysis: As of February 5, 2026, ESAB shares were priced at $127.90, up 5.3% over the past year but trailing the S&P 500 by 6.8 percentage points, suggesting a cautious market outlook on its future growth.
  • Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is expected to benefit from ongoing infrastructure investments and manufacturing growth, making it sensitive to economic cycles and government spending priorities.
NASDAQ.COM
8.5
02-27NASDAQ.COM
TimesSquare Capital Increases ESAB Stake by $30 Million
  • Share Acquisition Details: On February 6, 2026, TimesSquare Capital Management disclosed the purchase of 262,850 shares of ESAB, representing an estimated trade size of $30.08 million, indicating growing confidence in industrial manufacturing and infrastructure spending.
  • Value Increase: Following this transaction, the total value of ESAB shares held rose to $107.15 million, reflecting a $29.35 million increase at quarter-end, showcasing the dual impact of purchasing activity and stock price movements.
  • Portfolio Allocation: ESAB accounts for 1.61% of TimesSquare's assets under management, and while it does not rank among the top five holdings, the 38% increase in position suggests a bullish outlook on sectors related to construction and energy projects.
  • Industry Outlook: As a leading provider of welding and cutting solutions with approximately $2.8 billion in annual revenue, ESAB is well-positioned to benefit from ongoing infrastructure investments, making it an attractive option for investors sensitive to economic cycles.
seekingalpha
8.5
02-18seekingalpha
Cencora and Covetrus Enter Definitive Merger Agreement
  • Merger Overview: Cencora and Covetrus have entered into a definitive agreement to merge MWI Animal Health with Covetrus, creating a comprehensive animal health platform, with the transaction valuing MWI at an enterprise value of $3.5 billion, exceeding Cencora's current book value, indicating strong market optimism about the merger.
  • Cash and Equity Structure: Upon closing, Cencora will receive $1.25 billion in upfront cash, $800 million in preferred equity, and $1.45 billion in common equity, resulting in a 34.3% non-controlling stake in the combined company, thereby enhancing its market position in the animal health sector.
  • Financial Guidance Reaffirmed: Cencora reaffirmed its fiscal 2026 financial guidance, projecting operating income growth between 11.5% and 13.5%, indicating that the company can maintain robust growth while integrating OneOncology, which boosts investor confidence.
  • Strategic Market Implications: This merger not only enhances Cencora's asset value and market share but also provides a stronger competitive edge in the rapidly growing animal health market, expected to drive future business growth and innovation.
seekingalpha
8.5
02-10seekingalpha
Cencora Prices $3 Billion in Senior Notes Offering
  • Financing Scale: Cencora successfully priced $1.5 billion in senior notes across five different maturities, demonstrating strong capital market capabilities despite a slight market reaction with shares down 0.90%.
  • Note Rates: The notes range from 3.950% to 5.650%, reflecting market assessments of the company's credit risk, with higher rates potentially increasing future financial costs and impacting profitability.
  • Maturity Structure: The notes have maturities ranging from 2029 to 2056, providing a flexible financing structure that helps Cencora meet capital needs in the coming years while supporting its business expansion strategy.
  • Market Expectations: The offering is expected to close on February 13, 2026, with Cencora projecting an 11.5%-13.5% operating income growth for 2026, indicating confidence in future performance despite current stock price challenges.
Businesswire
8.5
02-10Businesswire
Cencora Prices $1.5 Billion Senior Notes Offering
  • Financing Scale: Cencora announced a $1.5 billion offering of five different senior notes with varying maturities, including 3.950% notes due in 2029, 4.250% notes due in 2030, 4.600% notes due in 2033, 4.900% notes due in 2036, and 5.650% notes due in 2056, demonstrating the company's robust capital market financing capabilities.
  • Use of Proceeds: The net proceeds from this offering will be used to repay amounts outstanding under Cencora's 364-Day Term Credit Agreement dated January 12, 2026, which was utilized to partially fund Cencora's acquisition of OneOncology, indicating the company's strategic focus on financial integration post-acquisition.
  • Underwriting Team: The offering is being managed by a consortium of leading banks including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo Securities, reflecting strong market confidence in Cencora and its significant position within the industry.
  • Compliance Statement: Cencora emphasized that this offering does not constitute an offer to sell or solicit offers to buy the notes, and sales may be unlawful in certain states or jurisdictions, highlighting the company's commitment to compliance with securities laws.
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
Wall Street analysts forecast COR stock price to rise
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
Current: 0.000
sliders
Low
400.00
Averages
415.38
High
440.00
BofA
Allen Lutz
Neutral
maintain
$360 -> $380
AI Analysis
2026-03-06
New
Reason
BofA
Allen Lutz
Price Target
$360 -> $380
AI Analysis
2026-03-06
New
maintain
Neutral
Reason
BofA analyst Allen Lutz raised the firm's price target on Cencora (COR) to $380 from $360 and keeps a Neutral rating on the shares. McKesson (MCK) "quietly" received a new National Drug Code for a biosimilar version of Neulasta a few weeks ago and while investors may be skeptical of McKesson's ambitions here, the firm frames "why this initial investor reaction could be wrong" based on seven large biosimilars coming to market over the next few years, including four that are directly addressable. The firm raised its McKesson target to reflect optionality on co-manufacturing and raised its Cencora (COR) target as well to reflect similar optionality.
Barclays
NULL -> Overweight
maintain
$400 -> $425
2026-02-13
Reason
Barclays
Price Target
$400 -> $425
2026-02-13
maintain
NULL -> Overweight
Reason
Barclays raised the firm's price target on Cencora to $425 from $400 and keeps an Overweight rating on the shares.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cencora Inc (COR.N) is 19.33, compared to its 5-year average forward P/E of 14.69. For a more detailed relative valuation and DCF analysis to assess Cencora Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
14.69
Current PE
19.33
Overvalued PE
16.97
Undervalued PE
12.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
10.79
Current EV/EBITDA
13.79
Overvalued EV/EBITDA
12.42
Undervalued EV/EBITDA
9.17

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.14
Current PS
0.19
Overvalued PS
0.16
Undervalued PS
0.11

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

run based on daily
Intellectia · 80 candidates
Ticker
Name
Market Cap$
top bottom
SPOT logo
SPOT
Spotify Technology SA
103.40B
COR logo
COR
Cencora Inc
68.24B
AFL logo
AFL
Aflac Inc
56.90B
MSCI logo
MSCI
MSCI Inc
44.25B
ONC logo
ONC
BeOne Medicines AG
40.49B
ED logo
ED
Consolidated Edison Inc
37.48B

Whales Holding COR

P
Pacer Advisors, Inc.
Holding
COR
+11.43%
3M Return
B
Boston Partners Global Investors, Inc.
Holding
COR
+10.37%
3M Return
D
Dakota Wealth, LLC
Holding
COR
+7.05%
3M Return
D
Distillate Capital Partners LLC
Holding
COR
+6.65%
3M Return
T
TimesSquare Capital Management, LLC
Holding
COR
+6.56%
3M Return
D
Donaldson Capital Management LLC
Holding
COR
+6.34%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cencora Inc (COR) stock price today?

The current price of COR is 352.19 USD — it has decreased -2.66

What is Cencora Inc (COR)'s business?

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

What is the price predicton of COR Stock?

Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is415.38 USD with a low forecast of 400.00 USD and a high forecast of 440.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cencora Inc (COR)'s revenue for the last quarter?

Cencora Inc revenue for the last quarter amounts to 85.93B USD, increased 5.45

What is Cencora Inc (COR)'s earnings per share (EPS) for the last quarter?

Cencora Inc. EPS for the last quarter amounts to 2.87 USD, increased 14.80

How many employees does Cencora Inc (COR). have?

Cencora Inc (COR) has 51000 emplpoyees as of March 10 2026.

What is Cencora Inc (COR) market cap?

Today COR has the market capitalization of 70.38B USD.